The goal of quantitative proteomics is to both identify and quantify a broad range of proteins and peptides. Targeted quantification continues to grow in importance as an increasing number of ‘potential’ protein biomarkers need to be verified / validated to confirm or refute their ultimate utility. This need for better quantification strategies drives technology development, pushing for increased throughput with increasingly lower detection levels. Increased throughput is required as larger sample numbers must be analyzed for verification / validation, which often means accelerated chromatography. This can increase the chance of interferences that could confound robust quantification which drives the need for higher selectivity strategies. Getting quantitative coverage of both high and low abundant precursors is a combination of both sensitivity and selectivity improvements as well as dynamic range increases. Recent MS innovations have also enabled a resurgence in data independent acquisition strategies which are proving to play an important role in targeted proteomics for early stage verification work. Technology progress in a variety of these key LCMS acquisition attributes will be explored.